By Peter Hassett, Director of Strategy, Patient Consent, IQVIA Technologies
Electronic consent (eConsent) technology has existed for nearly 20 years in various iterations. Even so, sponsors overall have taken a cautious approach to using eConsent, piloting it on individual studies but refraining from incorporating it across all pipelines in clinical operations.
The COVID-19 pandemic has shown us, however, that this “decade of dabbling” is over. To put the rapid pace of changein perspective, IQVIA’s eConsent solution saw a significant increase in volume—from about 30,000 patient consent transactions per year before the pandemic to up to 50,000 transactions per day at peak times of enrollment for highprofile vaccine trials.
Through this experience, IQVIA Technologies and its clients now know that the only way to capture the benefits of eConsent in site satisfaction, study operations, and sponsor oversight is to commit to widescale adoption across the enterprise and connect it to the broader trial experience. IQVIA Complete Consent is the next generation of eConsent solutions designed to overcome all the major barriers to success.